

## Exclusive Interview with Global Head of Maternal & Paediatric Regulatory Policy - Novartis

SMi speaks to some of their key note presenters about paediatric trials and regulations in the run up to the 8th annual conference on Paediatric Clinical Trials

LONDON, LONDON, UNITED KINGDOM, February 11, 2014 /EINPresswire.com/ -- SMi invites you

"

A more cohesive international regulatory collaboration would be expected to lead to minimization of duplicative or unnecessary studies..."

**Novartis** 

to attend the 8th annual <u>Paediatric Clinical Trials</u> conference, taking place in London on 31st March and 1st April 2014.

We are very grateful to our keynote speaker, Christina Bucci-Rechtweg, Head of Maternal & Paediatric Regulatory Policy from Novartis, for taking time out to give us her views on the biggest challenge for paediatric drug development, opportunity for global harmonisation of paediatric clinical trial regulation and lessons learned from

the FDASIA case study.

"A more cohesive international regulatory collaboration would be expected to lead to minimization of duplicative or unnecessary studies and foster innovation in both the technical and clinical development realms to address the unmet medical needs of children"

To read the full interview you can visit the download centre at www.paediatric-trials.co.uk

Christina will be joined at the event by Novartis Global Scientific Affairs Senior Expert, David McIntosh, who will be presenting on vaccine trials verses antibiotic trials. When asked about his upcoming presentation, David commented:

"Whether it is an adult with a serious bacterial infection or a child with such an infection, it is likely that antibiotic treatment will be necessary. But with increasing antibiotic resistance and a decreasing pace of antibiotic development, vaccines against healthcare associated infections provide an opportunity not only to prevent infection but also to decrease antibiotic resistance. The talk on "Vaccine Trials Versus Antibiotic Trials" will discuss the pros and cons of prevention

versus cure, providing examples of the role of vaccines in decreasing antibiotic resistance. Key randomised controlled vaccine trials will be discussed and contrasted with key antibiotic trials – the risk of failure will also be highlighted."

To hear more about the fundamental aspects of Paediatric Clinical Trials with senior decision makers from the industry, those interested can register to attend the event at <a href="https://www.paediatrictrials.co.uk">www.paediatrictrials.co.uk</a>

The download centre will be updated with new content on a regular basis. For current updates and further interviews click here.

PAEDIATRIC CLINICAL TRIALS
31st March - 1st April 2014
The Kensington Close Hotel
London UK
<a href="http://www.paediatric-trials.co.uk">http://www.paediatric-trials.co.uk</a>

Teri Arri SMi Group Ltd +44 (0)20 7827 6162 email us here



This press release can be viewed online at: https://www.einpresswire.com/article/189994901

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.